Appropriate Use Of Alzheimer’s Disease Drug Aduhelm Should Focus On People With Mild Cognitive Impairment & Mild Dementia

The newly approved Alzheimer’s disease treatment aducanumab (trade name Aduhelm) is most appropriate for use by people with mild cognitive impairment (MCI) or mild dementia due to Alzheimer's disease, according to an expert panel, because the drug's safety and effectiveness has only been tested with that population. However, some pragmatic adjustments may be required for use of aducanumab outside of the trial setting. Efficacy and safety have been assessed in people with MCI due to Alzheimer’s disease and mild dementia due to Alzheimer’s disease confirmed by amyloid positron emission tomography (PET). However, efficacy and safety . . .